Dr. Steven M. Duffy
Claim this profileHematology Oncology Associates of Central New York-East Syracuse
Studies Cancer
Studies Lung Cancer
18 reported clinical trials
38 drugs studied
Area of expertise
1Cancer
HER2 positive
Stage III
ER positive
2Lung Cancer
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Steven M. Duffy is currently running
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Steven M. Duffy
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Steven M. Duffy has experience with
- Biospecimen Collection
- Pembrolizumab
- Carboplatin
- Atezolizumab
- Durvalumab
- Venetoclax
Breakdown of trials Steven M. Duffy has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven M. Duffy specialize in?
Steven M. Duffy focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved HER2 positive patients, or patients who are Stage III.
Is Steven M. Duffy currently recruiting for clinical trials?
Yes, Steven M. Duffy is currently recruiting for 12 clinical trials in East Syracuse New York. If you're interested in participating, you should apply.
Are there any treatments that Steven M. Duffy has studied deeply?
Yes, Steven M. Duffy has studied treatments such as Biospecimen Collection, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Steven M. Duffy?
Apply for one of the trials that Steven M. Duffy is conducting.
What is the office address of Steven M. Duffy?
The office of Steven M. Duffy is located at: Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York 13057 United States. This is the address for their practice at the Hematology Oncology Associates of Central New York-East Syracuse.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.